在多发性硬化症中伴随性抑郁症的多元性

Kaarina Kowalec¹, Kathryn C Fitzgerald², Amber Salter²+16

• ¹From the College of Pharmacy (K.K.), Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada; Department of Medical Epidemiology & Biostatistics (K.K., A.H., S.H., Y.L.), Karolinska Institutet, Stockholm, Sweden; Department of Neurology (K.C.F.), Johns Hopkins School of Medicine, Baltimore, MD; Department of Neurology (A.S.), UT Southwestern, Dallas, TX; Department of Internal Medicine (C.D., C.N.B., R.A.M.), Department of Psychiatry (J.B.), and Department of Community Health Sciences (J.B., R.A.M.), Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada; Department of Biostatistics (G.R.C., A.P., H.K.T.), University of Alabama at Birmingham; Department of Clinical Health Psychology (L.A.G.), and Department of Rheumatology (C.A.H.), Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada; Icahn School of Medicine at Mount Sinai (F.L.), New York, NY; Department of Clinical Neuroscience (K.A.M.), Karolinska Institutet, Stockholm, Sweden; Department of Community Health Sciences (S.B.P.), Cumming School of Medicine, University of Calgary, Alberta, Canada; and Department of Neurology (J.S.W.), McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston. kaarina.kowalec@gmail.com.+1